Learn more about ILUVIEN

DME_header_woman

ILUVIEN is a CONTINUOUS MICRODOSINGTM Delivery system engineered to deliver inflammation-suppressing fluocinolone acetonide (FAc) to treat DME.1

  • Designed specifically for intraocular use.1
  • Nonbioerodable polyimide tube, the same material used in the haptics of many intraocular lenses.1
iluvien_suppress_inflammation

 

Corticosteroids inhibit inflammatory responses to a variety of inciting agents.1

FAc inhibits inflammatory responses such as:

  • Edema
  • Fibrin deposition
  • Capillary dilation
  • Leukocyte migration
  • Capillary proliferation
  • Fibroblast proliferation
  • Deposition of collagen
  • Scar formation associated with inflammation
 

Engineered for CONTINUOUS MICRODOSINGTM Delivery

DME_header_woman

Starting at day 1, ILUVIEN delivers a continuous submicrogram dose of FAc from a nonbioerodable polyimide implant.1,4

  • ILUVIEN contains 0.19 mg of the corticosteroid FAc, which is continuously released from a nonbioerodable, intravitreal, polyimide implant and inhibits inflammatory responses to a variety of inciting agents.1
  • The release of fluocinolone acetonide occurs in a near zero order fashion—meaning, there is minimal burst at the beginning and the level of drug released stays fairly constant.1,4
Iluvien_Vitro_Delivery_4c continuous-microdosing-logo

Proven efficacy from a single implant

DME_header_woman

ILUVIEN provided significant improvement in vision as measured by an increase of ≥ 15 letters from baseline in BCVA at 24 months.1,3

  • The safety and efficacy of ILUVIEN for the treatment of diabetic macular edema (DME) was studied vs. sham control in two 3-year pivotal studies (FAME A and FAME B).1, 3
  • 28.7% of patients treated with ILUVIEN during the FAME Study (FAME A and FAME B) saw an increase in visual acuity compared to 16.2% of sham control group patients.1,3

Iluvien_Increase_Letters_4c_flat

Iluvien_Estimated_Differences_4c

 

Maintained Reduction in Retinal Thickness

In ILUVIEN pivotal studies, mean retinal thickness was reduced and maintained throughout the 36-month study period.4,5

Iluvien_Retinal_Thickness_4c_flat

ILUVIEN was studied in patients whose DME persisted or recurred despite treatment.1,6

ILUVIEN was assessed in 2 prospective, randomized, multicenter, double-masked, parallel 3-year studies (FAME A and FAME B) of patients with DME who had previously been treated with laser photocoagulation.

  • Primary endpoint: Proportion of patients in whom vision had improved by ≥ 15 letters from baseline in best corrected visual acuity (BCVA) at 24 months.
  • Patients were treated with either ILUVIEN or sham injection (2:1).
  • All patients were allowed to receive rescue treatment for persistent edema any time after week 6 for persistent or recurrent DME, if necessary.

ILUVIEN was studied in patients whose DME persisted or recurred despite treatment1,5

DME_header_woman
  • Patients were treated with either ILUVIEN, 0.5 µg/d FAc, or sham injection (2:2:1).
  • Control patients received a sham injection.
  • Primary endpoint: Proportion of patients in whom vision had improved by ≥ 15 letters from baseline in best corrected visual acuity (BCVA) at 24 months.
  • All patients were allowed to receive rescue treatment for persistent edema any time after week 6 for persistent or recurrent DME, if necessary.
  • No patients enrolled in the phase 3 clinical trial were treatment naive. All had been treated with at least one prior macular laser treatment.
The sham injection consisted of the needle hub being pressed against the globe of the eye to simulate the injection of an implant.
clinical-studies-FAME-graph

Most Common Ocular Reported Adverse Events in the ILUVIEN Phase 3 Clinical Trials1

DME_header_woman

Ocular adverse reactions for patients in the ILUVIEN Phase 3 clinical trials were consistent with the use of ophthalmic corticosteroid treatment. 1

  • In controlled studies, the most common adverse reactions reported were cataract development (ILUVIEN 82%, sham 50%) and intraocular pressure evaluation of ≥10 mmHg (ILUVIEN 34%, sham 10%).
  • The median time to cataract reporting in patients treated with ILUVIEN was 12 months and 19 months for patients in the sham group.1
  • The median time to cataract surgery was 15 months for both ILUVIEN and sham groups.1

Iluvien_Cataract_Extraction

 

Iluvien_Adverse_Reactions_4c

Mean IOP remained steady throughout the studies1

mean-iop-during-the-iluvien-phase3

Summary of ILUVIEN IOP elevation from the ILUVIEN Phase 3 clinical trials

  • 34% of patients had IOP elevation ≥ 10 mm Hg from baseline, as compared to 10% with a sham
  • 20% of patients had IOP elevation ≥ 30 mm Hg from baseline, as compared to 4% with a sham

CONTINUOUS MICRODOSINGTM Delivery for Continuous Therapy

DME_header_woman
continuous-microdosing-logo

ILUVIEN is administered in the office setting using a specially designed applicator.

 

  • ILUVIEN is inserted into the vitreous cavity via a 25-gauge needle.
  • Each implant contains 0.19 mg fluocinolone acetonide (FAc) and is engineered to provide a submicrogram release at an initial rate of 0.25 µg/day lasting 36 months.

 

ILUVIEN is supplied in a sterile, single-use, preloaded custom applicator.

  • Packaged in a sealed tray that should be stored at room temperature between 59ºF and 86ºF.

dosing-injection-splashcontinuous-microdosing-logo

For more information regarding ILUVIEN administration, please refer to:

Subscribe for Updates

Enter your email address to stay up-to-date on the latest ILUVIEN® news.

  • No Thanks
  • This field is for validation purposes and should be left unchanged.